Tumor necrosis factor (TNF) is an inflammatory cytokine expressed by human fetal liver cells (HFLCs) after infection with cell culture-derived hepatitis C virus (HCV). TNF has been reported to increase entry of HCV pseudoparticles into hepatoma cells and inhibit signaling by interferon alpha (IFNa), but have no effect on HCV-RNA replication. We investigated the effects of TNF on HCV infection of and spread among Huh-7 hepatoma cells and primary HFLCs. METHODS: Human hepatoma (Huh-7 and Huh-7.5) and primary HFLCs were incubated with TNF and/or recombinant IFNA2A, IFNB, IFNL1, and IFNL2 before or during HCV infection. We used 2 fully infectious HCV chimeric viruses of genotype 2A in these studies: J6/JFH (clone 2) and Jc1(p7-nsGluc2A) (Jc1G), which encodes a secreted luciferase reporter. We measured HCV replication, entry, spread, production, and release in hepatoma cells and HFLCs. RESULTS: TNF inhibited completion of the HCV infectious cycle in hepatoma cells and HFLCs in a dose-dependent and time-dependent manner. This inhibition required TNF binding to its receptor. Inhibition was independent of IFNa, IFNb, IFNL1, IFNL2, or Janus kinase signaling via signal transducer and activator of transcription. TNF reduced production of infectious viral particles by Huh-7 and HFLC, and thereby reduced the number of infected cells and focus size. TNF had little effect on HCV replicons and increased entry of HCV pseudoparticles. When cells were incubated with TNF before infection, the subsequent antiviral effects of IFNs were increased. CONCLUSIONS: In a cell culture system, we found TNF to have antiviral effects independently of, as well as in combination with, IFNs. TNF inhibits HCV infection despite increased HCV envelope glycoproteinmediated infection of liver cells. These findings contradict those from other studies, which have reported that TNF blocks signal transduction in response to IFNs. The destructive inflammatory effects of TNF must be considered along with its antiviral effects.
Y ears of intensive study of the hepatitis C virus (HCV) have borne fruit in an array of highly effective, direct-acting antiviral drugs (DAAs) that target specific steps in HCV replication and virion assembly. Although DAAs have the potential to cure almost everyone who is treated, the majority of the estimated 130-200 million people worldwide who have chronic HCV infection [1] [2] [3] have poor access to modern health care, and have not yet been diagnosed, let alone treated. 4, 5 Issues such as screening, cost, comorbidities, and advanced liver disease may affect treatment uptake. Genotype-specific differences in drug sensitivity and the emergence of resistant strains also may influence treatment efficacy. Patients cured by DAA treatment are not protected reliably against re-infection. 6 A prophylactic vaccine is not yet available. 7 In addition, HCV remains an important model for studies of acute and chronic viral infection.
Many studies have shown reduced interferon (IFN)a/b induction and response in HCV-infected cells. HCV may dampen IFNa/b induction through viral protease-mediated cleavage of mitochondrial antiviral signaling protein (MAVS) and TIR domain containing adapter inducing IFNb (TRIF), key signal transducers involved in viral RNA recognition (reviewed by Horner and Gale 8 
and Li and Lemon 9
). HCV may counteract the antiviral actions of exogenous IFNs through a number of interactions with effector molecules. 8, 9 Despite this multilayered attack on innate immunity, HCV induces expression of IFNls and IFNstimulated genes in infected primary liver cells. 10, 11 Hundreds of IFN-stimulated genes that are expressed in the infected liver partially control but do not eliminate HCV during acute infection (reviewed by Dustin et al 12 ). Tumor necrosis factor-a (TNFa) is a pleiotropic cytokine produced by a variety of cell types including cytotoxic T cells, natural killer cells, endothelial cells, dendritic cells, monocytes, and macrophages. TNFa is a type II transmembrane protein trimer; a soluble form of TNFa can be released after proteolytic processing. Both cell-associated and cell-free TNFa are biologically active. TNFa can bind to 1 of 2 receptors with different downstream effects. domain protein, leading to activation of nuclear factor-kB, c-Jun N-terminal kinase, p38, and cell death pathways; integration of multiple downstream signals determines the effects of TNFR1 signal transduction. 14 Although TNFa is considered an inflammatory cytokine, it may contribute to control of viral infections by induction of antiviral gene expression or apoptosis. TNFa can mediate antiviral activities by itself 15, 16 and in synergy with IFNs (reviewed by Bartee and McFadden 17 ). In hepatocytes, TNFa was reported to inhibit hepatitis B virus (HBV) gene expression and replication, and to synergize with IFNg. [18] [19] [20] Hepatocytes also express TNFa after HCV infection, as we reported for cultured human fetal liver cells (HFLCs) infected with HCV. 10 Other investigators have reported that HCV induced TNFa transcription and protein release in Huh-7 hepatoma cells and primary human hepatocytes. 21 Hepatocyte induction of TNFa may occur independently of viral replication because both UV-inactivated virus and poly I:C (a Toll-like receptor 3 agonist) stimulated TNFa expression and release in a manner dependent on Toll-like receptor signaling. 10, 21 TNFa long has been associated with viral hepatitis: patients with acute or chronic viral hepatitis, including HCV and HBV, had increased serum TNFa protein levels 22, 23 ; hepatocytes from patients with HCV and HBV expressed TNFa messenger RNA and protein. 24 Initial studies of the impact of TNFa on HCV replication were not promising: in a subgenomic replicon system, TNFa had no effect on HCV replication. 25 Work from Fletcher et al 26 suggested that TNFa enhanced HCV entry in a hepatoma cell line expressing CD81. TNFa has been reported to support 21 and antagonize 27 IFNa/b signaling in Huh-7 hepatoma cells. Here, we report that TNFa inhibits HCV infection in Huh-7 hepatoma cells and in primary HFLCs. TNFa potently inhibits a late step in HCV infection via a mechanism independent of IFN binding or signal transduction.
Materials and Methods

Tissue Culture
Unless otherwise indicated, tissue culture media and additives were purchased from Life Technologies (Warrington, UK). Huh-7 and Huh-7.5 hepatoma cells were maintained in Dulbecco's modified Eagle medium supplemented with 5% (Huh-7.5) or 10% (Huh-7) heat-inactivated fetal bovine serum (Biosera, Nuaille, France) and 1Â nonessential amino acids.
HFLCs
De-identified fetal livers (gestation, 16-20 wk) were procured through the Human Developmental Biology Resource at the Institute of Child Health at University College (London, UK). Tissue collection was approved by The National Research Ethics Service (Research Ethics Committee reference 08/ H0712/34þ5). Cells were prepared and cultured as described previously. 28 Culture medium was aspirated and replaced every 2 days.
Replicon Assay
Huh-7 cells were prepared in T225 cm 2 flasks: half were pretreated with TNFa for 16 hours. Cells were trypsinized and washed 3Â with cold phosphate-buffered saline (PBS) followed by electroporation with in vitro-transcribed subgenomic or full-length HCV RNA as indicated (5 mg electroporated into 1.2 Â 10 7 cells). Electroporated cells were seeded at 2 Â 10 4 per well in 96-well plates. Cells were washed at 6 hours and subsequently at each harvesting time point. No drug selection was applied to replicon-bearing cultures.
Production and Quantitation of Cell Culture-produced HCV
We used 2 fully infectious HCV chimeric viruses of genotype 2A in these studies: J6/JFH (clone 2) 29 is highly infectious but does not encode a reporter, and Jc1(p7-nsGluc2A) (Jc1G) 30 encodes a secreted Gaussia princeps luciferase reporter. Viral stocks were prepared essentially as described previously. 31 Briefly, in vitro-transcribed viral RNA (5 mg) was electroporated into Huh-7.5 cells (1.2 Â 10 7 ). Virus was collected in Dulbecco's modified Eagle medium containing 1.5% heatinactivated fetal bovine serum and 1% nonessential amino acids, and was concentrated in a pressurized stirred cell using Amicon Ultracel-100K filters (Millipore, Billerica, MA). Infectivity titers were determined by limiting dilution titration on naive Huh-7.5 cells 32 and are presented as the median tissue culture infectious dose (TCID 50 ).
HCVcc Infection
Unless otherwise indicated, clone 2 was used at a multiplicity of infection (MOI) of 0.01 TCID 50 /cell for Huh-7 and Huh-7.5 cells, and 3 or 10 (depending on the availability of high-titer virus preparations) TCID 50 /cell for HFLCs. Jc1G was used at an MOI of 0.1 TCID 50 /cell for Huh-7 and Huh-7.5 cells, and 3 or 10 TCID 50 /cell for HFLCs. At time 0, virus was added to cells for 6 hours; cells then were washed 3 times in complete medium. Medium, cytokines, and drugs were replaced and cultures continued from this point, which was considered þ6 hours.
EDITOR'S NOTES
BACKGROUND AND CONTEXT
Human liver cells express tumor necrosis factor (TNF) following exposure to hepatitis C virus (HCV). Macrophages, T, and NK cells may also produce TNF during HCV infection.
NEW FINDINGS
Exogenous TNF inhibited completion of the HCV infectious cycle in human liver cells and hepatoma cell lines, dramatically reduces production of infectious viral particles.
LIMITATIONS
It is not yet known to what degree this mechanism may affect viral spread within the liver in HCV patients.
IMPACT
This study shows an unexpected antiviral role for TNF, a pro-inflammatory cytokine. Further investigation is needed to learn whether TNF limits production of infectious HCV in chronically infected patients.
HCV Pseudoparticles
HCV pseudoparticles (HCVpp) were produced in 293T cells cotransfected with HCV E1E2 expression plasmids and pNL4-3.Gluc.R-E-as described previously. 33 
Cytokines, Drugs, and Antibodies
Recombinant human TNFa, IFNa2a, IFNb, IFNl1, and IFNl2 were purchased from Peprotech (Rocky Hill, NJ) and prepared according to the manufacturer's recommendations. Stocks were prepared as single-use aliquots and stored at -80 C. Ruxolitinib was purchased from Selleckchem and used at a final concentration of 3 mmol/L. Danoprevir, an inhibitor of the HCV NS3-4A protease, was purchased from Selleckchem (Houston, TX) and used at 2 mmol/L. Etanercept (Amgen, Thousand Oaks, CA) kindly was provided by the Kennedy Institute of Rheumatology and was stored in single-use aliquots at 4 C. Anti-CD81 (clone JS81, no azide-low endotoxin) was purchased from BD Biosciences (San Jose, CA). The viral IFN antagonists B18R 34 and 136R 35 were purchased from Affymetrix (Santa Clara, CA) and Biotechne (Minneapolis, MN), respectively. Cytokines, antagonists, and drugs were replaced at each media change unless otherwise indicated.
Measurement of Cell-Free and Intracellular Infectious Virus
Cell-free HCV was collected from the supernatants of infected cultures. To prepare intracellular infectious virus, infected cells were washed 3 times with serum-free media; an aliquot of serum-free media then was added to the well and plates were subjected to 3 freeze-thaw cycles to release intracellular virus. Lysates were centrifuged (480 Â g) to remove cell debris. Infectious titers were determined as described. 32 
HCV-RNA Quantitation
Total RNA was extracted from tissue culture supernatants and freeze-thawed cell lysates using High Pure Viral RNA kits (Roche, Diagnostics, Burgess Hill, UK) or from washed cells using RNeasy minikits (Qiagen, Manchester, UK). RNA was eluted in 40 mL. A total of 5 mL RNA (one eighth of the total) was used for RNA quantitation. HCV RNA was detected by quantitative reverse-transcription polymerase chain reaction using the Eragen Multicode-RTx method 36 (Eragen Biosciences, Madison, WI) using primers to the 5' untranslated region of the HCV genome (5'-GGCTCCATCTTAGCCC-3' and 5'-/56-FAM//iMe-isodC/GCTCACGGACCTTTCA-3'), and quantified using a synthetic HCV RNA standard (Apath LLC, New York, NY).
Messenger RNA Quantitation
Total cellular RNA was prepared from cultured Huh-7 or HFLCs using RNeasy minikits. Complementary DNA synthesis, primers, real-time quantitative reverse-transcription polymerase chain reaction, and analysis were performed as we have reported previously. 10 
Gaussia Luciferase Replication Assay
To measure Jc1G replication, Huh-7 cells were plated in a 96-well plate and infected at a MOI of 0.1 for 6 hours. Cells were washed, media were replaced, and supernatants were harvested for a 6-hour background reading. Supernatants were harvested at the indicated times after infection, with extensive washing at each time point. Secreted luciferase was measured using the Renilla Luciferase Assay System (Promega, Southhampton, UK) and a Berthold TriStar2 multimode reader LB 942 (Berthold Technologies GmbH & Co, Bad Wildbad, Germany).
Flow Cytometry
Immunostaining for HCV NS5A was performed as previously described 30 using Alexa 647-conjugated monoclonal antibody 9E10. 31 Cells were analyzed on a BD LSRII (BD Biosciences, San Jose, CA). Data were analyzed using FlowJo version 10 (FlowJo LLC, Ashland, OR).
Assaying Viral Spread
Huh-7.5 cells expressing an HCV-dependent fluorescent reporter 37 were pretreated (16 h) with TNFa or control medium, then infected for 6 hours with clone 2 (MOI, 0.01). Infections were performed in 6-well plates, using a different (F) Effects of TNFa, etanercept, and danoprevir on HCV infection in HFLCs. Cells (n ¼ 6 wells/condition) were treated with 20 ng/mL TNFa ± 1 mg/mL etanercept, 2 mmol/L danoprevir, or media control before and during infection with Jc1G. Secreted luciferase was measured 96 hours after the start of infection. Box-and-whisker plot, whiskers represent the minimum and maximum values. P values were calculated by (A, top, and D) 2-way analysis of variance and (A, bottom, and E and F) 1-way analysis of variance. ***P < .001; ****P < .0001. Dan, danoprevir; RLU, relative light units; T, time.
plate for each time point. Infected cells were washed, media and TNFa were replaced, and plates were returned to culture. From this point until cells were fixed, care was taken to prevent plate movement and minimize mixing; thus, media and cytokines were not replaced during the assay. At each time point, an infected plate was selected, washed with PBS, and fixed (10 min) with 3.7% formaldehyde. Wells were washed 3 times with PBS and permeabilized (5 min) with 0.2% Triton X-100 (MP Biomedicals, Santa Ana, CA), washed 3 times with PBS, stained (10 minutes) with 2 ng/mL 4 0 ,6- Anti-CD81 was added as indicated 2 hours before the addition of pseudoparticles bearing envelope proteins from HCV (H77 or Con1) or control RD114, as indicated. After 6 hours, cultures were washed 3 times and culture was continued in complete medium. Secreted luciferase was measured 72 hours after infection. *P < .05; ****P < .0001.
diamidino-2-phenylindole (DAPI), and washed 3 times again. Cells were viewed using an Olympus inverted microscope (IX73) (Olympus, Southend-on-Sea, UK). DAPI and red fluorescent protein (RFP) were excited using 400 nm/565 nm light-emitting diode laser sources and detected using the 405/561 fluorescence filters. Images were taken at 10Â magnification and processed using cellSens (Olympus) and CellProfiler (cellprofiler.org). The CellProfiler workflow was Figure 3 . Spread of infection in Huh-7.5 cells expressing an HCV-dependent fluorescent reporter. Cells were cultured in complete media ± 20 ng/mL TNFa as indicated (see the Materials and Methods section for details). Cells were fixed and stained with DAPI at the indicated times after infection. RFP localizes to the nucleus in infected cells. Magnification, 10Â; scale bars: 100 mm.
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as follows: DAPI þ nuclei were identified, and a 5-pixel perinuclear space was defined. Mean RFP fluorescence intensities were measured for each nucleus and perinuclear space. The ratio of the mean nuclear:perinuclear space intensities was calculated for each cell. Cells with a ratio greater than 1 were counted as infected.
Statistics
Graphing and statistical analysis were performed with GraphPad Prism 6.0h (GraphPad Software, San Diego, CA). Data are presented as means ± SD of at least triplicate samples, and all experiments were repeated a minimum of 3 times. Statistical significance was determined by using the Mann-Whitney test, 1-way analysis of variance, or 2-way analysis of variance, as indicated, and corrected for multiple comparisons using the Tukey post test. Statistical significance was indicated as follows: *P < .05; **P < .01, ***P < .001, ****P < .0001, or as not significant.
Results
TNFa Inhibits HCV Infection in Huh-7 Cells
Huh-7 hepatoma cells were treated overnight with medium or TNFa and then infected with fully infectious HCV genotype 2 chimeric viruses; culture was continued in the presence of either medium or TNFa. Supernatants were collected at 24-hour intervals to measure reporter expression. TNFa inhibited reporter expression in a dosedependent manner ( Figure 1A) . IC 50 values averaged less than 1 ng/mL (range, 0.1-1.74 ng/mL); IC 90 averaged 19.14 ng/mL (range, 1.38-37.86 ng/mL) in 3 experiments. Flow cytometric analysis showed that fewer cells were infected in TNFa-treated cultures, although infected cells expressed comparable levels of NS5A ( Figure 1B ). Inhibition was time-dependent, with the degree of inhibition increasing over time. The duration of TNFa exposure also influenced the degree of inhibition ( Figure 1C ). Although cells treated with TNFa beginning at or after virus addition showed little change in reporter expression, those treated with TNFa beginning 18 or 24 hours before HCV infection showed a 10-fold decrease in reporter expression; those treated starting 40 hours before virus addition showed a 2-log decrease in reporter expression ( Figure 1D) . It was not possible to determine whether new gene expression or protein synthesis was required for the inhibitory effect because Huh-7 cells could not be cultured for long periods with actinomycin D or cycloheximide (data not shown). Huh-7 cells remained viable and proliferated to a similar extent in the presence or absence of TNFa (Supplementary Figure 1) . To confirm that HCV growth inhibition was the result of the effects of TNFa rather than a contaminant, we performed cultures in the presence of the TNFa antagonist etanercept. Inclusion of this inhibitor restored the growth of HCV in the presence of exogenous TNFa ( Figure 1E ). TNFa also inhibited HCV growth in primary HFLCs, and this effect also was blocked by etanercept ( Figure 1F ). Levels of viral RNA were reduced in TNFa-treated cultures (Supplementary Figure 2) .
Together, these results show that TNFa inhibits HCV infection or growth in liver cells, that the inhibition is dose-and time-dependent, and that the inhibition is dependent on TNFa binding to its receptor on liver cells.
TNFa Inhibits HCV Spread
The observation that TNFa inhibits HCV infection was unexpected given published reports from other groups using different systems. To understand the basis for this difference, we measured the effects of TNFa on different stages of HCV infection. To ascertain whether TNFa inhibited HCV-RNA replication, we electroporated subgenomic JFH1 luciferase reporter replicons into TNFatreated Huh-7 cells. The results of this experiment showed that replication was not inhibited by TNFa (Figure 2A) . As a control, no replication was seen using a replicon containing a mutation within the NS5B polymerase (GNN). These results were consistent with a previous report that TNFa did not affect replication of an HCV subgenomic replicon. 25 Expression of full-length genotype 1 replicons also was not inhibited for at least 5 days; however, expression of a full-length genotype 2A (J6/JFH) replicon, which may produce infectious virus, 31 was inhibited by approximately 25% ( Figure 2B ).
Consistent with a report showing that TNFa enhanced HCV envelope glycoprotein-mediated infection of HepG2 hepatoma cells expressing CD81, 26 we observed that TNFa enhanced infection by lentiviral pseudoparticles bearing HCV glycoproteins ( Figure 2C , left and center). TNFa did not overcome the entry block caused by the addition of anti-CD81 monoclonal antibody JS81. Of note, TNFa also enhanced infection by pseudoparticles bearing an unrelated glycoprotein from the feline endogenous retrovirus RD114 ( Figure 2C, right) .
Because TNFa reduced the number of infected cells ( Figure 1B) without inhibiting replication or entry (Figure 2) , we investigated its effects in an assay of viral spread (Figures 3 and 4) . We used Huh-7.5 cells expressing the HCV-dependent fluorescent reporter described by Jones et al. 37 Cells were infected with clone 2, and the spread of infection was monitored microscopically over the ensuing days. Although HCV spread rapidly in control cultures, TNFa-treated cultures showed reduced viral spread (Figures 3 and 4A ) and reduced focus size (Figures 3 and  4B) . Note that these cultures were left undisturbed (and /well) were cultured in 6-well plates and treated with TNFa for 16 hours before the start of infection. HCVcc clone 2 was added to wells at a MOI of 0.01. Wells were washed (3 times) 6 hours after the start of infection. Virus was collected from supernatants and lysed cells at the indicated times. (E) HCV growth and levels of infectious virus in HFLCs cultured with or without 20 ng/mL TNFa. Cells (2 Â 10 5 /well) were grown in collagen-coated 24-well plates. After 5 days, cells were treated for 16 hours with medium ± 20 ng/mL TNFa. Virus (Jc1G, left; clone 2, right) then was added at a MOI of 10 for 6 hours; cells then were washed extensively and culture was continued in medium without or with TNFa. Supernatants were collected at 24-hour intervals for measurement of luciferase (left) and infectious virus (right). Fluids were pooled for the TCID 50 assay. We were unable to measure infectious virus in cell lysates. **P < .01; ****P < .0001. unfed) to prevent mixing, which would have accelerated viral spread.
One possible explanation for the reduced viral spread is that TNFa prevents virus assembly or egress from infected cells. To ascertain whether TNFa affects production or release of infectious virus, we measured virus levels over time in cultures treated with TNFa or medium before and during infection with HCVcc clone 2 (MOI, 0.1). TNFa-treated cultures had profoundly reduced levels of infectious virus in both cell-free and cell-associated fractions ( Figure 4C) . A similar result was obtained with primary HFLCs, although the overall production of infectious virus was low ( Figure 4D ); we were unable to measure intracellular infectious virus in HFLC cultures.
TNFa Inhibits HCV Infection Independently of IFNa/b and IFNl
We hypothesized that TNFa acted by triggering autocrine IFN production. To define the role of IFN signaling in the effects of TNFa, we treated cells with a variety of inhibitors of IFN signaling or binding ( Figure 5A ). We used 2 poxvirus-derived soluble IFN antagonists, B18R (which blocks IFNa/b-receptor binding) and 136R (which preferentially blocks IFNl-receptor binding) to antagonize IFN signaling in Huh-7 cell cultures. B18R blocked the antiviral effects of IFNa but not those of TNFa. Similarly, 136R blocked the antiviral effects of IFNl but not those of TNFa. A mixture of B18R þ 136R also did not reverse the antiviral effect of TNFa. The Jak1/Jak2 antagonist, ruxolitinib, blocked the effects of IFNa and IFNl, but not those of TNFa. The inhibitory effect of TNFa was blocked by etanercept, as also seen in Figure 1E . As shown in Figure 5B , HFLC cultures treated with ruxolitinib remained sensitive to TNFa. These results indicate that TNFa mediates an antiviral effect independent of type I or type III IFN binding or Jak signaling. TNFa did not induce expression of type I or type III IFNs ( Figure 5C ), or of typical IFN-stimulated genes such as OAS1, IFIT1, or ISG15 (Supplementary Figure 3) .
Interactions Between TNFa and IFNs
Although the earlier-described results indicated that TNFa can work independently of IFN binding or Jakmediated IFN-receptor signaling, they do not address the effects of TNFa stimulation on IFN responses, or vice versa. To examine the effects of TNFa on IFN responses, we performed cross-wise, dose-response experiments in which Huh-7 hepatoma cells were treated simultaneously with TNFa, IFNb, IFNl, or combinations of TNFa and an IFN. The presence of TNFa increased the antiviral effects of suboptimal levels of IFNs ( Figure 6A ). We also tested the effects of sequential treatment with TNFa and IFNs in different combinations as shown in Figure 6B . Cells were pretreated overnight (cytokine 1), then washed and infected with HCVcc in the presence of cytokine 2. Cytokine 2 treatment was continued throughout the course of infection, and HCV growth was estimated by luciferase measurement. Cells treated with TNFa as cytokine 1 showed reduced HCV growth, even when cytokine 2 was absent ( Figure 6B , cytokine 1 ¼ TNFa vs cytokine 1 ¼ none). TNFa-pretreated cells showed increased sensitivity to IFNa as cytokine 2 ( Figure 6B , cytokine 1 ¼ TNFa vs cytokine 1 ¼ none when cytokine 2 ¼ IFNa). Likewise, IFNa pretreatment enhanced the antiviral effects of TNFa as cytokine 2. These results indicate that TNFa pretreatment increases the antiviral effects of IFNs, and that IFN pretreatment increases the antiviral effects of TNFa.
Discussion
TNFa, a cytokine with diverse roles in inflammation and immunity, is produced by a variety of cell types including monocytes/macrophages and cytotoxic T cells. We and other investigators have shown that cultured liver cells express TNFa after HCV infection. 10, 21 Here, we show that TNFa mediates antiviral activity against HCV. IFN binding and Jak-mediated signal transduction are not required for this antiviral effect, suggesting that TNFa can act independently of IFNs. TNFa acts at a late stage of the HCV infection cycle. Thus, TNFa does not inhibit and indeed may modestly enhance HCV pseudoparticle entry, suggesting that it does not inhibit viral entry. Persistence of HCV replicons that do not spread from cell to cell largely is unaffected by TNFa. TNFa inhibits a step after viral entry and translation of incoming RNA, possibly by reducing or blocking assembly and spread of infectious virus. Both intracellular and cellfree infectious virus levels are reduced. Of note, TNFa had little effect against yellow fever virus infection in Huh-7 cells (Supplementary Figure 4) , and enhanced yellow fever virus infection in dendritic cells from 2 of 3 donors (Supplementary Figure 5) . Studies are ongoing to determine how TNFa affects infection by other virus families in addition to those reported by other groups. 15, 16, 18, 19 These results may be considered unexpected given previous results from other laboratories. The differences between our observations and those of others highlight the evolution of HCV study systems. Frese et al 25 reported that TNFa did not affect replication of a subgenomic HCV RNA in a replicon-bearing cell line. Here, we observed that although replication of a subgenomic HCV replicon was not sensitive to TNFa, viral growth and spread were sensitive to this cytokine. This result was not attainable before the advent of systems permitting a complete infectious cycle in vitro. Similarly, Fletcher et al 26 showed that TNFa enhanced HCV and HCVpp entry into polarized HepG2 cells expressing CD81. We also found that TNFa-treated Huh-7 cells show a modest increase in HCVpp entry. This increase in entry is not HCV-specific because we observed a similar result with pseudoparticles bearing glycoproteins from the unrelated feline endogenous retrovirus RD114; this is consistent with the observations reported by Fletcher et al 26 showing comparable increases in entry of pseudoparticles bearing non-HCV glycoproteins. Indeed, Fletcher et al 26 also observed that although TNFa-treated hepatoma cells supported increased HCV entry, there was no associated change in viral RNA replication. 26 Later events, including HCV spread, were not measured in the aforementioned study. 26 In our hands, TNFa-treated liver cells sometimes had an initial increase in HCV reporter expression at early time points (eg, in primary HFLCs) ( Figure 4D ). This transient increase is consistent with enhancement of initial viral entry ( Figure 2C ), followed by inhibition of viral spread (Figures 3  and 4) .
Interactions between TNFa and antiviral cytokines such as IFNa have been the subject of conflicting reports. Although TNFa is reported to potentiate the antiviral effects of IFNs against an array of DNA and RNA were cultured without or with cytokines ± the antagonists B18R, 136R, ruxolitinib, etanercept, or B18R þ 136R, as indicated. HCVcc Jc1G was added at a MOI of 0.1 for 6 hours, cultures were washed, and media ± cytokines ± antagonists were replaced. Culture was continued for 96 hours and supernatants were sampled at 96 hours for measurement of luciferase. P values were calculated by 1-way analysis of variance using "cytokine only" for each graph as control. ****P < .0001. (B) HCV infection in HFLCs treated with 3 mmol/L ruxolitinib ± 20 ng/mL TNFa. Cells were infected with HCVcc Jc1G or clone 2 (MOI, 10) for 6 hours, then washed extensively and culture was continued in the presence of ruxolitinib ± TNFa as indicated.
Supernatants were collected at 24-hour intervals for the measurement of luciferase and cellfree infectious virus. (C) Expression of IFN genes. HFLCs (n ¼ 3 wells/point/ time point) were treated with 10 ng/mL TNFa, 10 U/ mL IFNb, 0.1 ng/mL IFNl1, or 5 mg/mL polyI:C as indicated. RNA was prepared at the indicated times and subjected to quantitative reversetranscription polymerase chain reaction. mRNA, messenger RNA.
viruses, 15, 17, 38 the mechanisms behind such activities are not well understood. It has been proposed that TNFa acts in part by inducing expression of IFNb in some cell types (reviewed by Bartee et al 38 ) . We have shown that TNFa mediates an antiviral effect against HCV in the presence of antagonists of IFN binding and signal transduction, suggesting that TNFa can act independently of IFNs.
In contrast, other investigators have reported that TNFa inhibits IFN signal transduction in hepatoma cells by Figure 6 . TNFa increases the effects of IFNs. (A) Effects of simultaneous treatment with TNFa and cytokines. Cells (n ¼ 2 wells/point) were treated with TNFa at the indicated doses without or with IFNs as indicated. HCVcc (Jc1G: MOI, 0.1) was added for 6 hours; cells then were washed extensively and cytokines were replaced. Supernatants were collected for luciferase measurement 72 hours after infection. P values were calculated by 2-way analysis of variance and refer to the interaction between TNFa and each IFN. (B) Effects of sequential treatment with TNFa and IFNs. Cells (n ¼ 5 wells/point) were pretreated for 16 hours with no cytokine, 20 ng/mL TNFa, or 100 U/mL IFNa, as indicated (cytokine 1). They were infected with HCVcc (Jc1G: MOI, 0.1) for 6 hours, washed extensively, and then cultured with no cytokine (white bars), TNFa (red bars), IFNa (black bars), or TNFa þ IFNa (red/black striped bars) as indicated (cytokine 2) for the remainder of the experiment. Media were sampled for luciferase measurement after 96 hours. Fold change was calculated using the following equation:
. P values were calculated by 2-way analysis of variance and refer to the interaction between cytokines 1 and 2. *P < .05; **P < .01; ***P < .001; ****P < .0001.
stimulating expression of the ubiquitin-specific peptidase USP18. 27 Importantly, the studies reported by MacParland et al 27 did not address the impact of such signaling effects on viral growth or replication. To examine this question, we treated cells either simultaneously or sequentially with IFNs and TNFa, as shown in Figure 6 . TNFa did not antagonize the antiviral effects of IFNs.
TNFa antagonists are widely used clinically, while TNFa agonists are used or are in development for the treatment of certain malignancies. 39 Clinical therapy with TNFa antagonists appears to be generally safe in patients with autoimmune or inflammatory diseases and concurrent HCV infection, 40 although dramatic (>2 log 10 ) increases in viral load have been observed in a minority of patients. 41, 42 It is possible that TNFa plays a more important role in the control of HCV in some patients than in others. Importantly, TNFa is active both as a transmembrane precursor and as a soluble protein released from producer cells. 43, 44 The various TNFa antagonist drugs differ in their affinity for soluble and transmembrane TNFa and their effects on TNFa-producing cells, partially explaining their disparate clinical indications and contraindications (reviewed by Horiuchi et al 44 ). Certain antagonists may bind poorly to transmembrane TNFa, perhaps preserving the antiviral functions of TNFa-expressing cells.
The role of TNFa in the control of HCV infection in the human liver remains uncertain. Increased peripheral blood levels of TNFa have been reported in human beings with hepatitis of various etiologies 22, 23 ; the cellular origins of the cytokine are not known and may differ in different disease settings. Plasma levels of TNFa are increased significantly in patients with chronic HCV infection (Supplementary Figure 6) . Importantly, local concentrations of TNFa are likely to be higher in the infected liver. 26 Innate immune cells in the liver, including Kupffer cells, macrophages, and dendritic cells, express TNFa in response to pathogen-associated molecular patterns including those associated with HCV. 26 T-cell recognition of HCV-infected cells is key to spontaneous recovery, whereas exhaustion of HCV-specific T cells is a hallmark of persistent HCV infection. The polyfunctional T cells required for HCV clearance produce TNFa as part of their immune program. Loss of TNFa expression is a feature of T-cell exhaustion. 45 It is not straightforward to estimate the local concentration of cell-associated TNFa in the infected liver. Studies are ongoing to define the impacts of T-cell-associated and macrophage-associated TNFa on HCV infection. TNFa, by mediating antiviral activities alone and by potentiating the antiviral effects of IFNs, may contribute to the partial control of viral load that is a feature of even chronic HCV infection. Supplementary Figure 4 . Effects of TNFa on yellow fever virus infection of Huh-7 cells. Cells (n ¼ 2 wells/condition) were infected with wild-type Asibi (WT) or vaccine strain (17D) yellow fever virus at a MOI of 10 or 2, as shown. After 48 hours, infected cultures were harvested, fixed, and stained with a polyclonal antiserum to yellow fever NS4AB, followed by phycoerythrin-labeled donkey anti-rabbit IgG. Cells were analyzed on a FACSCalibur (BD Biosciences, Franklin Lakes, NJ) and data were analyzed using FlowJo software. Bar graphs show the results of duplicate samples. The frequency of infected cells was not significantly different between untreated and TNFa-treated cultures. YF, yellow fever. Three different donors (A, B, and C) were tested in parallel. Cells were infected with yellow fever virus 17D bearing a yellow fluorescent protein reporter. 2 After 72 hours, cells were harvested, fixed, and analyzed by flow cytometry on a BD FACSCalibur. Dendritic cells from 2 of the 3 donors showed increased levels of viral infection after TNFa treatment. FL3-H, Fluorescence 3-height; PerCP, peridinin chlorophyll protein complex.
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